Sanofi is linking arms with BioNTech under multiyear exclusive collaboration and license agreement targeting the discovery and development of up to five new cancer immunotherapies containing a mix of messenger RNAs, that could bring more than $1.5 billion to the latter’s books.
Sanofi is paying BioNTech $60 million in upfront and near-term milestone payments for rights to the candidates based on the latter’s technology, but the firm could receive over $300 million more in development, regulatory and commercial milestones and other payments, as well as sales-based royalties, for each product.
Under the terms of the deal, BioNTech also holds the option to co-develop and co-commercialise two of the five mRNA therapeutics products with Sanofi in the European Union and the US.
“The collaboration with Sanofi is groundbreaking: through using our broad suite of mRNA technologies and extensive tumor immunology understanding, it will allow us to develop a completely new class of cancer immune-therapeutics with Sanofi, which we believe will have a profound and deep impact on the treatment of cancer,” said BioNTech chief executive Ugur Sahin, commenting on the move.
Source: Pharma Times
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”